Ozan S. Kumru

University of Kansas — United States

Medicine · Health Sciences

20h-index1.7kcitations72works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(22), Protein purification and stability(18), Monoclonal and Polyclonal Antibodies Research(15), Viral gastroenteritis research and epidemiology(13), Animal Virus Infections Studies(9)

Publications72 total

Developability assessments with four mRNA-LNP vaccine formulations comparing mouse immunogenicity, structural attributes, and stability profiles
Journal of Pharmaceutical Sciences·2026Open Access
Developability assessments with four mRNA-LNP vaccine formulations comparing mouse immunogenicity, structural attributes, and stability profiles.
2025
Developability assessments with four mRNA-LNP vaccine formulations comparing mouse immunogenicity, structural attributes, and stability profiles (Dataset)
2025
Characterizing the Aggregation Propensity of an Anti-HIV-1 Bispecific Antibody in Two Different Formulation Buffers During Agitation Stress
2025
Characterizing the Aggregation Propensity of an Anti-HIV-1 Bispecific Antibody in Two Different Formulation Buffers During Agitation Stress (Dataset)
2025
Two recombinant cytomegalovirus antigens formulated with the SPA14 adjuvant system: Impact of temperature, pH and excipients on the stability of each antigen and adjuvant component
Journal of Pharmaceutical Sciences·2025Open Access
Two Recombinant Cytomegalovirus Antigens Formulated with the SPA14 Adjuvant System: Impact of Temperature, pH and Excipients on the Stability of each Antigen and Adjuvant Component (Dataset)
2025
Effects of aluminum-salt, CpG and emulsion adjuvants on the stability and immunogenicity of a virus-like particle displaying the SARS-CoV-2 receptor-binding domain (RBD) (Dataset)
2023
Author Correction: A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates
Nature Communications·2023· 2 citedOpen Access
Formulation development and comparability studies with an aluminum-salt adjuvanted SARS-CoV-2 Spike ferritin nanoparticle vaccine antigen produced from two different cell lines (Dataset)
2023
Formulation development and comparability studies with an aluminum-salt adjuvanted SARS-CoV-2 spike ferritin nanoparticle vaccine antigen produced from two different cell lines
Vaccine·2023· 4 citedOpen Access
Effects of aluminum-salt, CpG and emulsion adjuvants on the stability and immunogenicity of a virus-like particle displaying the SARS-CoV-2 receptor-binding domain (RBD)
Human Vaccines & Immunotherapeutics·2023· 3 citedOpen Access
Effects of aluminum-salt, CpG and emulsion adjuvants on the stability and immunogenicity of a virus-like particle displaying the SARS-CoV-2 receptor-binding domain (RBD)
2023Open Access
Correlating physicochemical and biological properties to define critical quality attributes of a rAAV vaccine candidate
Molecular Therapy — Methods & Clinical Development·2023· 10 citedOpen Access
Correlating physicochemical and biological properties to define critical quality attributes of a recombinant AAV vaccine candidate (Dataset)
2023
Nanoalum formulations containing aluminum hydroxide and CpG 1018 adjuvants: the effect on stability and immunogenicity of a recombinant SARS-CoV-2 RBD antigen (Dataset)
2023Open Access
Nanoalum Formulations Containing Aluminum Hydroxide and CpG 1018TM Adjuvants: The Effect on Stability and Immunogenicity of a Recombinant SARS-CoV-2 RBD Antigen
Vaccines·2023· 10 citedOpen Access
A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates
Nature Communications·2023· 76 citedOpen Access
Formulation Studies to Develop Low-cost, Orally-delivered Secretory IgA Monoclonal Antibodies for Passive Immunization Against Enterotoxigenic Escherichia coli (Dataset)
2023Open Access
Formulation Studies to Develop Low-Cost, Orally-Delivered Secretory IgA Monoclonal Antibodies for Passive Immunization Against Enterotoxigenic Escherichia coli
Journal of Pharmaceutical Sciences·2023· 1 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

David B. Volkin(41), Sangeeta B. Joshi(38), C. Russell Middaugh(16), Harry Kleanthous(8), J. Christopher Love(8), Sakshi Bajoria(8), Neil C. Dalvie(7), Sergio A. Rodriguez‐Aponte(7), Kawaljit Kaur(7), Christopher A. Naranjo(7), John M. Hickey(7), Swathi R. Pullagurla(7), Prashant Kumar(6), Ryan S. Johnston(5), Judith M. Silverman(5), Payton A. Weidenbacher(5), Mrinmoy Sanyal(5), Natalia Friedland(5), Jonathan Do(5), Ya-Chen Cheng(5)